Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded to "Hold" at DZ Bank

Key Points

• DZ Bank upgraded Bayer from a "strong sell" to a "hold" on Thursday, while other firms like UBS and Barclays have recently raised their ratings to "buy" and "overweight," respectively.
• The stock carries a consensus rating of Moderate Buy, based on 2 Strong Buy, 5 Buy, 1 Hold and 1 Sell analyst recommendations.
• Bayer's most recent quarter reported EPS of $0.18 (in line with estimates) and revenue of $13.24 billion (slightly above expectations), and the company set FY 2026 guidance at 1.251–1.400 EPS (analysts expect about 1.31 EPS).

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by DZ Bank from a "strong sell" rating to a "hold" rating in a report issued on Thursday,Zacks.com reports.

BAYRY has been the topic of a number of other research reports. Zacks Research cut Bayer Aktiengesellschaft from a "hold" rating to a "strong sell" rating in a research note on Tuesday, March 24th. UBS Group raised Bayer Aktiengesellschaft from a "neutral" rating to a "buy" rating in a research note on Monday, March 16th. Finally, Barclays raised Bayer Aktiengesellschaft from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy".

Bayer Aktiengesellschaft Trading Down 0.3%

Bayer Aktiengesellschaft stock opened at $11.75 on Thursday. The stock has a market cap of $46.18 billion, a P/E ratio of -10.59 and a beta of 0.70. Bayer Aktiengesellschaft has a fifty-two week low of $5.70 and a fifty-two week high of $14.85. The firm's fifty day moving average price is $12.03 and its 200-day moving average price is $10.44. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting analysts' consensus estimates of $0.18. The business had revenue of $13.24 billion for the quarter, compared to analysts' expectations of $13.08 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.